An interventional study of Theranova 400 dialyzer and Elisio-17H dialyzer in End Stage Renal Disease, sponsored by Vantive Health LLC. Completed at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-14.
Sponsored by Vantive Health LLC (formerly part of Baxter Healthcare Corporation) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Kidney Failure, Chronic by Baxter Healthcare Corporation — none open to participants now, none under way, none of them phase 3. Kidney Failure, Chronic · Baxter Healthcare Corporation.
Among the 33 studies in Kidney Failure, Chronic by Baxter Healthcare Corporation, this one is the 6th largest by enrollment of the 29 interventional ones that give a count, is the only one that started in 2017, is one of 22 with no phase, and was the 24th registered.
2,114 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
Browse Kidney Failure, Chronic studies →None of the 33 studies in Kidney Failure, Chronic by Baxter Healthcare Corporation is open now. The open studies under Kidney Failure, Chronic, anywhere →
Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 1 started in 2017.
This study's enrollment of 172 is above the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 43 across the 29 interventional studies, 55 across the 4 observational. Of the 31 that completed or were terminated, 7 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Vantive Health LLC, one of the names counted as Baxter Healthcare Corporation. Under that name alone:
Vantive Health LLC is the lead sponsor of 55 studies on the registry; 3 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 33 studies in Kidney Failure, Chronic by Baxter Healthcare Corporation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study evaluates the efficacy and safety of the Theranova 400 dialyzer compared with Elisio-17 H dialyzer in end stage renal disease patients receiving hemodialysis treatment. Efficacy will be determined by the removal of middle molecules (with different molecular size) from the blood compartment. Safety will be evaluated by maintaining pre-dialysis serum albumin levels and other safety events including laboratory tests and adverse events.
Patients will undergo 3 dialysis sessions per week, for 24 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Three (3) dialysis sessions per week in an in-center setting over 24-week period.
Device: Theranova 400 dialyzer
Three (3) dialysis sessions per week in an in-center setting over 24-week period.
Device: Elisio-17H dialyzer
Patients should continue with their pre-study hemodialysis prescriptions (in terms of treatment time, blood flow rate and dialysate flow rate) and prescriptions should be kept stable throughout the study.
Also known as: MCO-Ci 400 Dialyzer, medium cut-off dialysis membrane
Patients should continue with their pre-study hemodialysis prescriptions (in terms of treatment time, blood flow rate and dialysate flow rate) and prescriptions should be kept stable throughout the study.
Reduction Ratio of Lambda Immunoglobulin FLC at Week 24
FLC=free light chains
Time frame: Week 24
Pre-dialysis Serum Level of Albumin at Week 24
Time frame: Week 24
Reduction Ratio of Lambda Immunoglobulin FLC at Week 4 and Week 24
FLC=free light chains
Time frame: Week 4 and Week 24
Reduction Ratio of Complement Factor D
CFD=complement factor D
Time frame: Week 4 and 24
Reduction Ratio of κ FLC
κ FLC = Kappa Free light chains
Time frame: Week 4 and 24
Reduction Ratio of Interleukin 6
IL-6=interleukin 6
Time frame: Week 4 and 24
Reduction Ratio of Tumor Necrosis Factor Alpha
TNFα=tumor necrosis factor alpha
Time frame: Week 4 and 24
Reduction Ratio of β2-microglobulin
β2=beta 2
Time frame: Week 4 and 24
Change From Baseline in Pre-dialysis β2-microglobulin at Week 24
Time frame: Baseline, Week 24
Kt/Vurea
Kt/Vurea = Dimensionless number used to quantify hemodialysis and peritoneal dialysis adequacy.
Time frame: Week 4, 8, 12, 16, 20, 24
Change From Baseline in Pre-dialysis Serum Albumin by Visit
Time frame: Baseline, Week 4, 8, 12, 16, 20, 24
Change From Baseline in Pre-dialysis Factor VII by Visit
Time frame: Baseline, Week 12, Week 24
Change From Baseline in Pre-dialysis Protein C by Visit
Time frame: Baseline, Week 12, Week 24
Change From Baseline in Pre-dialysis Vitamin A by Visit
Time frame: Baseline, Week 4, Week 24
nPNA (nPCR)
nPNA=normalized Protein equivalent of Nitrogen Appearance, and nPCR=normalized Protein Catabolic Rate.
Time frame: Week 4, 8, 12, 16, 20, 24
Change From Baseline in Pre-dialysis Factor II by Visit
Factor II (Prothrombin)
Time frame: Baseline, Week 12, Week 24
Change From Baseline in Sodium (mmol/L) at End of Study (up to Week 24)
Time frame: Baseline and Week 24
Change From Baseline in Potassium (mmol/L) at End of Study (up to Week 24)
Time frame: Baseline and Week 24
Change From Baseline in Calcium (mmol/L) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Phosphate (mmol/L) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Chloride (mmol/L) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Bicarbonate (mmol/L) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Glucose (mmol/L) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Prothrombin Time (Sec) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Prothrombin Intl. Normalized Ratio at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Activated Partial Thromboplastin Time (Sec) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Hematocrit (L/L) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Hemoglobin (g/L) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Erythrocyte Mean Corpuscular Hemoglobin (pg) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Erythrocyte Mean Corpuscular HGB Concentration (g/L) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Erythrocyte Mean Corpuscular Volume (fL) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Platelets at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Erythrocytes at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Leukocytes at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Basophils (%) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Eosinophils (%) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Lymphocytes (%) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Monocytes (%) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Neutrophils (%) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Pre-Dialysis Blood Urea Nitrogen (mmol Urea/L) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Post-Dialysis Blood Urea Nitrogen (mmol Urea/L) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in BUN Reduction Ratio at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Creatinine (μmol/L) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Kt/Vurea by Visit
Time frame: Week 4, Week 8, Week 12, Week 16, Week 20, Week 24
Change From Baseline in Vitamin A (μmol/L) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Cholesterol (mmol/L) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in HDL Cholesterol (mmol/L) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in LDL Cholesterol (mmol/L) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Triglycerides (mmol/L) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Alkaline Phosphatase (U/L) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Alanine Aminotransferase (U/L) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Aspartate Aminotransferase (U/L) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Direct Bilirubin (μmol/L) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Bilirubin (μmol/L) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Gamma Glutamyl Transferase (U/L) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Protein (g/L) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Globulin (g/L) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in High-sensitivity C-reactive Protein (mg/L) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Prothrombin Activity (%) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Albumin (g/dL) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Factor XIV Activity (%) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Tumor Necrosis Factor (pg/mL) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Factor VII Activity (%) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Lambda Light Chain, Free (mg/L) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Interleukin 6 (pg/mL) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Complement Factor D (mcg/mL) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Kappa Light Chain, Free (mg/L) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
Change From Baseline in Beta-2 Microglobulin (mg/L) at End of Study (up to Week 24)
Time frame: Baseline, Week 24
| Milestone | Theranova 400 | Elisio-17H |
|---|---|---|
| Started | 86 | 86 |
| Completed | 65 | 65 |
| Not completed | 21 | 21 |
| Withdrew: Adverse event | 2 | 3 |
| Withdrew: Protocol violation | 1 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Renal transplantation | 2 | 0 |
| Withdrew: Switch to peritoneal dialysis | 1 | 0 |
| Withdrew: Death | 3 | 2 |
| Withdrew: Change to another dialysis center | 2 | 2 |
| Withdrew: Missing 3 consecutive study treatments | 5 | 6 |
| Withdrew: Miscellaneous | 2 | 2 |
| Withdrew: Other | 0 | 1 |
FLC=free light chains
| percentage ratio | Theranova 400 | Elisio-17H |
|---|---|---|
| Reduction Ratio of Lambda Immunoglobulin FLC at Week 24 | 32.156 ± 12.602 | 17.514 ± 12.7235 |
| g/dL | Theranova 400 | Elisio-17H |
|---|---|---|
| Pre-dialysis Serum Level of Albumin at Week 24 | 4.030 ± 0.2843 | 4.018 ± 0.3935 |
FLC=free light chains
| percentage ratio | Theranova 400 | Elisio-17H |
|---|---|---|
| Week 4 | 39.3 ± 14.487 | 19.88 ± 11.394 |
| Week 24 | 33.29 ± 10.96 | 17.19 ± 12.863 |
CFD=complement factor D
| percentage ratio | Theranova 400 | Elisio-17H |
|---|---|---|
| Week 4 | 36.78 ± 26.499 | 11.71 ± 27.71 |
| Week 24 | 38.09 ± 11.233 | 14.55 ± 11.298 |
κ FLC = Kappa Free light chains
| percentage ratio | Theranova 400 | Elisio-17H |
|---|---|---|
| Week 4 | 65.63 ± 18.566 | 49.74 ± 15.111 |
| Week 24 | 59.27 ± 13.068 | 43.91 ± 14.882 |
IL-6=interleukin 6
| percentage ratio | Theranova 400 | Elisio-17H |
|---|---|---|
| Week 4 | -4.62 ± 49.378 | -22.21 ± 69.618 |
| Week 24 | -0.85 ± 46.214 | -14.83 ± 43.574 |
TNFα=tumor necrosis factor alpha
| percentage ratio | Theranova 400 | Elisio-17H |
|---|---|---|
| Week 4 | 47.29 ± 9.966 | 37.9 ± 8.892 |
| Week 24 | 44.48 ± 10.215 | 34.52 ± 10.673 |
β2=beta 2
| percentage ratio | Theranova 400 | Elisio-17H |
|---|---|---|
| Week 4 | 75.67 ± 8.2 | 64.86 ± 8.903 |
| Week 24 | 73.64 ± 10.426 | 65.41 ± 9.428 |
| mg/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Pre-dialysis β2-microglobulin at Week 24 | -3.95 ± 5.614 | -1.16 ± 6.128 |
Kt/Vurea = Dimensionless number used to quantify hemodialysis and peritoneal dialysis adequacy.
| Kt/Vurea | Theranova 400 | Elisio-17H |
|---|---|---|
| Week 4 | 1.58 ± 0.266 | 1.58 ± 0.427 |
| Week 8 | 1.62 ± 0.288 | 1.51 ± 0.316 |
| Week 12 | 1.58 ± 0.294 | 1.55 ± 0.328 |
| Week 16 | 1.56 ± 0.268 | 1.59 ± 0.48 |
| Week 20 | 1.57 ± 0.297 | 1.55 ± 0.371 |
| Week 24 | 1.51 ± 0.31 | 1.54 ± 0.467 |
| g/dL | Theranova 400 | Elisio-17H |
|---|---|---|
| Week 4 | -0.08 ± 0.244 | 0 ± 0.203 |
| Week 8 | -0.11 ± 0.254 | 0.00 ± 0.216 |
| Week 12 | -0.12 ± 0.289 | -0.04 ± 0.229 |
| Week 16 | -0.13 ± 0.335 | -0.03 ± 0.315 |
| Week 20 | -0.08 ± 0.279 | 0.02 ± 0.258 |
| Week 24 | 0.01 ± 0.250 | 0.04 ± 0.256 |
| percentage activity | Theranova 400 | Elisio-17H |
|---|---|---|
| Week 12 | 3.59 ± 24.057 | 7.79 ± 27.798 |
| Week 24 | 0.38 ± 34.572 | 9.19 ± 48.575 |
| percentage activity | Theranova 400 | Elisio-17H |
|---|---|---|
| Week 12 | 1.12 ± 15.711 | 1.76 ± 16.378 |
| Week 24 | 0.14 ± 19.376 | -1.78 ± 18.781 |
| μmol/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Week 4 | -0.29 ± 0.983 | -0.04 ± 0.939 |
| Week 24 | -0.33 ± 0.832 | -0.15 ± 1.096 |
nPNA=normalized Protein equivalent of Nitrogen Appearance, and nPCR=normalized Protein Catabolic Rate.
| g/kg/d | Theranova 400 | Elisio-17H |
|---|---|---|
| Week 4 | 0.983 ± 0.2473 | 1.056 ± 0.3088 |
| Week 8 | 1.013 ± 0.2380 | 1.023 ± 0.2936 |
| Week 12 | 0.971 ± 0.2573 | 1.030 ± 0.2664 |
| Week 16 | 1.022 ± 0.2869 | 0.971 ± 0.2881 |
| Week 20 | 0.988 ± 0.2666 | 1.024 ± 0.3366 |
| Week 24 | 0.947 ± 0.2450 | 1.012 ± 0.2891 |
Factor II (Prothrombin)
| percent activity | Theranova 400 | Elisio-17H |
|---|---|---|
| Week 12 | 3.45 ± 11.507 | 3.19 ± 13.284 |
| Week 24 | 3.85 ± 11.678 | 5.78 ± 15.394 |
| mmol/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Sodium (mmol/L) at End of Study (up to Week 24) | -0.20 ± 3.192 | 0.00 ± 3.671 |
| mmol/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Potassium (mmol/L) at End of Study (up to Week 24) | 0.08 ± 0.727 | -0.23 ± 0.665 |
| mmol/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Calcium (mmol/L) at End of Study (up to Week 24) | -0.06 ± 0.154 | -0.02 ± 0.151 |
| mmol/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Phosphate (mmol/L) at End of Study (up to Week 24) | -0.03 ± 0.438 | -0.19 ± 0.500 |
| mmol/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Chloride (mmol/L) at End of Study (up to Week 24) | 0.09 ± 3.488 | 0.43 ± 4.108 |
| mmol/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Bicarbonate (mmol/L) at End of Study (up to Week 24) | 1.31 ± 3.053 | 1.37 ± 3.080 |
| mmol/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Glucose (mmol/L) at End of Study (up to Week 24) | -0.20 ± 2.197 | 0.47 ± 2.858 |
| Sec | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Prothrombin Time (Sec) at End of Study (up to Week 24) | -0.04 ± 4.016 | -0.49 ± 6.305 |
| ratio | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Prothrombin Intl. Normalized Ratio at End of Study (up to Week 24) | -0.01 ± 0.341 | -0.05 ± 0.527 |
| Sec | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Activated Partial Thromboplastin Time (Sec) at End of Study (up to Week 24) | -0.82 ± 16.682 | -0.96 ± 15.424 |
| L/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Hematocrit (L/L) at End of Study (up to Week 24) | 0.03 ± 0.055 | 0.01 ± 0.042 |
| g/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Hemoglobin (g/L) at End of Study (up to Week 24) | 2.74 ± 15.569 | -0.11 ± 11.221 |
| pg | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Erythrocyte Mean Corpuscular Hemoglobin (pg) at End of Study (up to Week 24) | -0.12 ± 1.079 | -0.35 ± 1.153 |
| g/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Erythrocyte Mean Corpuscular HGB Concentration (g/L) at End of Study (up to Week 24) | -18.54 ± 16.053 | -15.12 ± 21.075 |
| fL | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Erythrocyte Mean Corpuscular Volume (fL) at End of Study (up to Week 24) | 4.88 ± 5.371 | 1.93 ± 4.778 |
| 10^9 cells/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Platelets at End of Study (up to Week 24) | -8.65 ± 41.711 | 7.99 ± 49.215 |
| 10^12 cells/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Erythrocytes at End of Study (up to Week 24) | 0.10 ± 0.482 | 0.04 ± 0.365 |
| 10^9 cells/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Leukocytes at End of Study (up to Week 24) | -0.22 ± 1.640 | 0.49 ± 2.464 |
| % of total white blood count (WBC) | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Basophils (%) at End of Study (up to Week 24) | 0.05 ± 0.369 | -0.02 ± 0.408 |
| % of total WBC | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Eosinophils (%) at End of Study (up to Week 24) | 0.17 ± 3.259 | -0.29 ± 2.397 |
| % of total WBC | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Lymphocytes (%) at End of Study (up to Week 24) | 0.14 ± 6.979 | -0.69 ± 8.052 |
| % of total WBC | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Monocytes (%) at End of Study (up to Week 24) | -0.49 ± 2.261 | -1.07 ± 3.479 |
| % of total WBC | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Neutrophils (%) at End of Study (up to Week 24) | 0.16 ± 8.744 | 1.98 ± 9.485 |
| mmol urea/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Pre-Dialysis Blood Urea Nitrogen (mmol Urea/L) at End of Study (up to Week 24) | -1.82 ± 5.299 | -0.69 ± 4.784 |
| mmol urea/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Post-Dialysis Blood Urea Nitrogen (mmol Urea/L) at End of Study (up to Week 24) | -0.53 ± 2.360 | -0.57 ± 2.066 |
| no unit | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in BUN Reduction Ratio at End of Study (up to Week 24) | 0.33 ± 9.298 | 0.68 ± 8.963 |
| μmol/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Creatinine (μmol/L) at End of Study (up to Week 24) | -17.45 ± 160.343 | -36.44 ± 153.168 |
| no unit | Theranova 400 | Elisio-17H |
|---|---|---|
| Week 4 | 1.58 ± 0.266 | 1.58 ± 0.427 |
| Week 8 | 1.62 ± 0.288 | 1.51 ± 0.316 |
| Week 12 | 1.58 ± 0.294 | 1.55 ± 0.328 |
| Week 16 | 1.56 ± 0.268 | 1.59 ± 0.480 |
| Week 20 | 1.57 ± 0.297 | 1.55 ± 0.371 |
| Week 24 | 1.51 ± 0.310 | 1.54 ± 0.467 |
| μmol/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Vitamin A (μmol/L) at End of Study (up to Week 24) | -0.35 ± 0.826 | -0.01 ± 0.899 |
| mmol/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Cholesterol (mmol/L) at End of Study (up to Week 24) | -0.19 ± 0.766 | -0.24 ± 0.705 |
| mmol/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in HDL Cholesterol (mmol/L) at End of Study (up to Week 24) | 0.04 ± 0.266 | -0.03 ± 0.276 |
| mmol/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in LDL Cholesterol (mmol/L) at End of Study (up to Week 24) | -0.07 ± 0.663 | -0.18 ± 0.807 |
| mmol/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Triglycerides (mmol/L) at End of Study (up to Week 24) | -0.15 ± 0.661 | -0.02 ± 0.672 |
| U/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Alkaline Phosphatase (U/L) at End of Study (up to Week 24) | -1.97 ± 37.783 | 2.19 ± 32.725 |
| U/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Alanine Aminotransferase (U/L) at End of Study (up to Week 24) | -2.17 ± 8.168 | -0.51 ± 8.018 |
| U/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Aspartate Aminotransferase (U/L) at End of Study (up to Week 24) | -0.75 ± 6.816 | -0.01 ± 5.870 |
| μmol/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Direct Bilirubin (μmol/L) at End of Study (up to Week 24) | 1.53 ± 2.603 | 0.23 ± 1.107 |
| μmol/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Bilirubin (μmol/L) at End of Study (up to Week 24) | -1.06 ± 2.960 | -0.66 ± 2.040 |
| U/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Gamma Glutamyl Transferase (U/L) at End of Study (up to Week 24) | -0.66 ± 22.587 | -1.68 ± 21.724 |
| g/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Protein (g/L) at End of Study (up to Week 24) | -1.55 ± 4.576 | -0.95 ± 4.223 |
| g/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Globulin (g/L) at End of Study (up to Week 24) | -2.07 ± 3.635 | -1.27 ± 3.216 |
| mg/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in High-sensitivity C-reactive Protein (mg/L) at End of Study (up to Week 24) | -0.96 ± 4.168 | -0.40 ± 4.600 |
| percentage activity | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Prothrombin Activity (%) at End of Study (up to Week 24) | 3.85 ± 11.678 | 5.78 ± 15.394 |
| g/dL | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Albumin (g/dL) at End of Study (up to Week 24) | 0.01 ± 0.250 | 0.04 ± 0.256 |
| percentage activity | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Factor XIV Activity (%) at End of Study (up to Week 24) | 0.14 ± 19.376 | -1.78 ± 18.781 |
| pg/mL | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Tumor Necrosis Factor (pg/mL) at End of Study (up to Week 24) | -0.47 ± 1.999 | 0.08 ± 1.645 |
| percentage activity | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Factor VII Activity (%) at End of Study (up to Week 24) | 0.38 ± 34.572 | 9.19 ± 48.575 |
| mg/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Lambda Light Chain, Free (mg/L) at End of Study (up to Week 24) | -19.40 ± 31.635 | 1.75 ± 29.946 |
| pg/mL | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Interleukin 6 (pg/mL) at End of Study (up to Week 24) | 0.20 ± 5.449 | 1.64 ± 6.473 |
| mcg/mL | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Complement Factor D (mcg/mL) at End of Study (up to Week 24) | 0.13 ± 4.742 | 1.89 ± 4.838 |
| mg/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Kappa Light Chain, Free (mg/L) at End of Study (up to Week 24) | -84.81 ± 97.359 | -43.01 ± 75.677 |
| mg/L | Theranova 400 | Elisio-17H |
|---|---|---|
| Change From Baseline in Beta-2 Microglobulin (mg/L) at End of Study (up to Week 24) | -3.95 ± 5.614 | -1.16 ± 6.128 |
Collected over AEs/SAEs were collected after the informed consent was signed and throughout the study (week 24), until the end of study visit (week 25-26).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Theranova 400 | 3/86 (3.5%) | 15/86 (17.4%) | 14/86 (16.3%) |
| Elisio-17H | 3/85 (3.5%) | 23/85 (27.1%) | 11/85 (12.9%) |
| Event | Theranova 400 | Elisio-17H |
|---|---|---|
| FLUID OVERLOADMetabolism and nutrition disorders | 1/86 | 3/85 |
| ACUTE MYOCARDIAL INFARCTIONCardiac disorders | 1/86 | 2/85 |
| NON-CARDIAC CHEST PAINGeneral disorders | 0/86 | 2/85 |
| ACUTE RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders | 0/86 | 2/85 |
| PYREXIAGeneral disorders | 2/86 | 0/85 |
| PNEUMONIAInfections and infestations | 2/86 | 1/85 |
| ANGINA PECTORISCardiac disorders | 0/86 | 1/85 |
| ATRIAL FIBRILLATIONCardiac disorders | 0/86 | 1/85 |
| BRADYCARDIACardiac disorders | 0/86 | 1/85 |
| CARDIAC ARRESTCardiac disorders | 1/86 | 1/85 |
| Event | Theranova 400 | Elisio-17H |
|---|---|---|
| PROCEDURAL HYPOTENSIONInjury, poisoning and procedural complications | 3/86 | 7/85 |
| NAUSEAGastrointestinal disorders | 6/86 | 1/85 |
| COUGHRespiratory, thoracic and mediastinal disorders | 6/86 | 3/85 |
| Age, Continuous(years) | Theranova 400 | Elisio-17H | Total |
|---|---|---|---|
| Mean | 58.5 ± 13.52 | 59.7 ± 12.4 | 59.1 ± 12.95 |
| Sex: Female, Male(Participants) | Theranova 400 | Elisio-17H | Total |
|---|---|---|---|
| Female | 32 | 35 | 67 |
| Male | 54 | 51 | 105 |
| Race/Ethnicity, Customized(Participants) | Theranova 400 | Elisio-17H | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 5 | 2 | 7 |
| Black or African American | 33 | 35 | 68 |
| Native Hawaiian or Other Pacific Islander | 3 | 3 | 6 |
| White | 40 | 42 | 82 |
| Other | 5 | 4 | 9 |
| Region of Enrollment(Participants) | Theranova 400 | Elisio-17H | Total |
|---|---|---|---|
| United States | 86 | 86 | 172 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2017 to primary completion in Oct 2018, 12 months.
Results were first posted in Dec 2020, 2 years 1 month after primary completion. A results delay was requested in Nov 2018.
Of 78 industry-sponsored interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 40. This study's 12 months is below that.
Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.